Cytoagents, Inc.
Small molecule pharmaceutical (GP1681) to treat severe influenza by modulating cytokine storm immune response
- Sector
- Biotech
- Headquarters
- Pittsburgh, PA
- Founded
- 2018
- Latest Form D
- $7M, May 2023
- Total capital
- $21.7M
- Federal grants
- $8.6M
- 8 awards · 2020–2025
- Rank in peer group#58 of 514
- Private capital raised
- $13.1M
- 2 Form D · last May 2023
- 41 months since last filing
- Federal contracts
- None on recordNo federal contract awards found.
- Granted patents
- 1
- 19 pending · first 2024
- Rank in peer group#186 of 514
Capital timeline
Latest events
- Federal grantHealth and Human S · Phase II · CTO1681 to prevent and mitigate cytokine release syndrome in multiple myeloma patients receiving CAR T-cell therapy$1.3M
- Federal grantHealth and Human S · Phase II · CTO1681 to prevent and mitigate cytokine release syndrome in CAR T-cell recipients$1M
- Federal grantHealth and Human S · Phase II · CTO1681 to prevent and mitigate cytokine release syndrome in CAR T-cell recipients$995K
- Private capital raisedForm D · SEC · 2nd filing$7M
- Federal grantHealth and Human S · Phase II · Preclinical development of an immunomodulatory agent capable of mitigating SARS-CoV-2 virus related hypercytokinemia$1M
- Private capital raisedForm D · SEC · 1st filing$6.1M
- Federal grantHealth and Human S · Phase II · Preclinical development of an immunomodulatory agent capable of mitigating influenza related hypercytokinemia$814K
Show 3 earlier federal awards
- Federal grantHealth and Human S · Phase II · Preclinical development of an immunomodulatory agent capable of mitigating SARS-CoV-2 virus related hypercytokinemia$1M
- Federal grantHealth and Human S · Phase II · Preclinical development of an immunomodulatory agent capable of mitigatinginfluenza related hypercytokinemia$1.7M
- Federal grantHealth and Human S · Phase II · Preclinical development of an immunomodulatory agent capable of mitigating influenza related hypercytokinemia$848K
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
Federal first
15months
from Cytoagents, Inc.’s first federal award to its first private round.
- First federal award · May 2020
- Health and Human S · $848K
- First Form D · Aug 2021
- $6.1M · 1st Form D
- Awards before first raise
- 4 awards
An association in public records, not a cause or a prediction.
Standing among 514 peers
Line = medianBiotech · Molecule
- Federal grants#58 · top 11%
- Granted patents#186 · top 36%
Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.
Founders and team
From SEC Form D filings- Anthony McCarleyDirectorNamed in SEC Form D filings
- Catherine MottDirectorNamed in SEC Form D filings
- John FriedmanDirectorNamed in SEC Form D filings
- Robert L FerrisDirectorNamed in SEC Form D filings
- Roy L PriebExecutive OfficerNamed in SEC Form D filings
- Stanley MarksDirectorNamed in SEC Form D filings
Show all 7 people
- Teresa WhalenExecutive Officer, DirectorNamed in SEC Form D filings
What it has protected
USPTO · 1 granted of 20- PendingMethod For Preparing Beraprost 314-D SodiumUSPTOApplication 19222873
- PendingCar T-cell Adjuvant TherapiesUSPTOApplication 18679999
- GrantedCompositions And Methods For Treating Coronavirus InfectionsUSPTOUS 12,042,503
Show all 20 patent records
- Method For Preparing Beraprost 314-D SodiumDec 4, 2025 · Application 19222873Pending
- Car T-cell Adjuvant TherapiesDec 5, 2024 · Application 18679999Pending
- Compositions And Methods For Treating Coronavirus InfectionsJul 23, 2024 · US 12,042,503Granted
- Chimeric Antigen Receptor (car) T-cell Adjuvant TherapiesNov 30, 2023 · Application 18325930Pending
- Bispecific Antibody TherapiesAug 3, 2023 · Application 18162344Pending
- Car T-cell Adjuvant TherapiesJun 2, 2022 · Application 17537687Pending
- Chimeric Antigen Receptor (car) T-cell Adjuvant TherapiesApplication 63347221Pending
- Bispecific Antibody TherapiesApplication 63304955Pending
- Car T-cell Adjuvant TherapiesApplication PCTUS2021061066Pending
- Compositions And Methods For Treating Coronavirus InfectionsApplication PCTUS2021017751Pending
- Car T-cell Adjuvant TherapiesApplication 63119085Pending
- Compositions And Methods For Treating Coronavirus InfectionsApplication 63057095Pending
- Compositions And Methods For Treating Coronavirus InfectionsApplication 63020342Pending
- Chimeric Antigen Receptor (car) T-cell Adjuvant TherapiesApplication PCTUS2025057281Pending
- Compositions And Methods For Treating CoronavirusApplication 62975369Pending
- Chimeric Antigen Receptor (car) T-cell Adjuvant TherapiesApplication 63725975Pending
- Method For Preparing Beraprost 314-D SodiumApplication 63653539Pending
- Chimeric Antigen Receptor (car) T-cell Adjuvant TherapiesApplication PCTUS2023067640Pending
- Bispecific Antibody TherapiesApplication PCTUS2023061664Pending
- Chimeric Antigen Receptor (car) T-cell Adjuvant TherapiesApplication 63482448Pending
Related companies, and why
- HCW Biologics Inc.Similar federal contract value in Biotech · null in contracts
- Onchilles Pharma, Inc.Similar federal contract value in Biotech · null in contracts
- IHP THERAPEUTICS, INC.Similar federal contract value in Biotech · null in contracts
- Aromyx CorpSimilar federal contract value in Biotech · null in contracts
- MODULO BIO, INC.Similar federal contract value in Biotech · null in contracts
- KAYOTHERA INCSimilar federal contract value in Biotech · null in contracts
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .